SG&A Expense Trends: TG Therapeutics, Inc. vs Merus N.V.

In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, TG Therapeutics, Inc. and Merus N.V. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, TG Therapeutics, Inc. experienced a significant increase in SG&A expenses, peaking in 2021 with a 550% rise from 2014 levels. This surge reflects their aggressive expansion and investment in marketing and administrative capabilities.

Conversely, Merus N.V. displayed a more gradual increase, with a notable 1,450% growth from 2015 to 2023. This steady rise indicates a strategic scaling of operations, aligning with their growth in the biopharmaceutical sector. The contrasting trends between these two companies highlight different strategic approaches in managing operational costs, offering valuable insights for investors and industry analysts alike.